Excited To See Biopharmatrend Com Cited In Ernst Young Ey S Latest

Excited to see BioPharmaTrend.com cited in Ernst & Young (EY)’s latest report, “How Emerging Technologies Are Enabling the Human-Machine Hybrid Economy” — part of their new EY Megatrends series. This in-depth piece explores how AI, robotics, brain-computer interfaces, and longevity research are accelerating us toward a hybrid era, one where human-machine collaboration pushes performance far beyond biological limits. 🔍 Key insights directly from the report: Enhanced workforces deliver 2.4× better performance, but leaders must address widening cognitive and physical divides. A study by MIT and Johns Hopkins involving 2,310 participants found that human-AI teams had 73% higher productivity and created higher-quality marketing content. In manufacturing, exoskeleton-supported workers experienced up to 60% less physical strain, while industry-wide implementations saw 20–60% injury reductions and 15–25% productivity gains. In healthcare, AI-assisted diagnostics increased fracture detection sensitivity from 72% to 80%, and specificity from 81% to 85%, while cutting diagnostic time by 30.8%.

In law, AI-powered contract review achieved 98% accuracy and cut review time from 92 minutes to 26 seconds. Investment in longevity research reached $8.5 billion in 2024, a 220% increase over the previous year, reflecting growing interest in technologies that may extend productive working lives. The article highlights urgent ethical and policy questions, including neural data privacy, cognitive autonomy, and the risk of an enhancement divide between those with access to augmentation and those without. Kudos to Beatriz Sanz Saiz for highlighting not just the tech, but the ethical, strategic, and societal shifts leaders need to navigate! It is a thought-provoking, even entertaining, and insightful weekend read, folks. Image credit: Ernst & Young

Read the full report here: https://www.ey.com/en_gl/megatrends/how-emerging-technologies-are-enabling-the-human-machine-hybrid-economy Thanks for posting this, the gains across sectors highlight how broad the shift has become. In this second video snippet from Episode 4 of the Zeroe[IN] Live Webinar Series “AI × Sustainability”, Farouk Jivani builds on the discussion by unpacking the real economics of AI adoption. He explains that AI is no longer a passing trend but a foundational layer of national competitiveness, with trillions being invested globally in infrastructure and enterprise deployment. The question is no longer if organizations will engage with AI, but how quickly and responsibly they will. Farouk points out that delaying adoption comes at a measurable cost.

Businesses lose $1.8 trillion annually in productivity, employees waste five hours a week searching for information, and manual workflows cost organizations $10–15 million per year on average. Through practical examples like invoice automation, where costs can drop from $13–16 to $1–6 per invoice, he illustrates how AI unlocks significant operational efficiencies and margin protection. Citing recent MIT research, Farouk notes that while AI leaders may not yet see immediate top-line growth, they are already realizing gains in efficiency, resilience, and competitiveness, proving that 'doing nothing' is no longer... This clip continues the “AI × Sustainability” discussion, exploring how enterprises can responsibly leverage technology to accelerate impact and build smarter, stronger systems. Interested to learn how Zeroe can help your organization move faster toward sustainability goals: 👉 https://lnkd.in/dVynbFKT Simulating carbon footprint with generative AI only adds value if it guides real decisions.

The key is to make scenarios comparable: clear functional unit, coherent boundaries and scopes, and versioned emission factors. With traceable data and documented assumptions, figures become useful and auditable, not merely illustrative. In this way, estimates stop being an isolated exercise and start informing concrete priorities. Governance underpins credibility: defined roles, change logs, and explanations of which variables drive results. Sensitivity analysis and validation against historical data reduce bias and prevent greenwashing, while security and privacy management protect sensitive information. Transparency and consistency turn each simulation into a reliable asset.

Impact comes when it is integrated into procurement, logistics, energy, and design with approval rules, thresholds, and periodic reviews. Starting with a focused scope and a stable baseline accelerates learning without sacrificing rigor. Tools like Syntetica or Vertex AI can help orchestrate data and scenarios discreetly, keeping the focus on clear, measurable decisions. #carbonfootprint #generativeAI #simulation #sustainability #data #governance #decarbonization #procurement #logistics #energy #productdesign #ESG https://ow.ly/TLnh50Xq8YP EY helps clients create long-term value for all stakeholders. Enabled by data and technology, our services and solutions provide trust through assurance and help clients transform, grow and operate.

Discover how EY insights and services are helping to reframe the future of your industry. How digital twin technology powers the future at Xcel Energy How Bristol Myers Squibb overhauled working capital to fund its future How St James’s Hospital's journey to cloud transformed cancer care Here we summarize select citations and press mentions of BiopharmaTrend reports and opinion articles. This list is far from being comprehensive, but it captures the types of organizations that rely on our insights:

At BiopharmaTrend, we dive deep into the most exciting areas of life sciences, from AI and digital health to neurotech and aging. Our content covers the latest in biotech innovations, clinical trials, and emerging startups, offering a comprehensive view of the future of healthcare. Partner with us to reach an engaged audience passionate about the cutting-edge developments shaping our bioeconomy and society. We are the official media partner of numerous top industry events in the pharmaceutical industry. Associate Director of Global Business Development & Licensing and Strategic Partnerships, AI Platforms at Insilico Medicine Fun fact to wrap up the week: Just 7 years after Apple achieved a market cap of $1T, Eli Lilly and Company just became the first pharma company ever to hit a $1T valuation.

🤯 A huge milestone for the industry! 💪🏼 📖 PS: If you missed it, here’s a BioPharmaTrend.com news article by Roman Kasianov on Insilico Medicine ’s recent $100M AI-driven drug discovery collaboration deal with Eli Lilly: https://lnkd.in/d2pteyDg Science & Tech Communicator | AI & Digital | Life Sciences | Chemistry Excited to see BioPharmaTrend.com cited in Ernst & Young (EY)’s latest report, “How Emerging Technologies Are Enabling the Human-Machine Hybrid Economy” — part of their new EY Megatrends series. This in-depth piece explores how AI, robotics, brain-computer interfaces, and longevity research are accelerating us toward a hybrid era, one where human-machine collaboration pushes performance far beyond biological limits. 🔍 Key insights directly from the report: Enhanced workforces deliver 2.4× better performance, but leaders must address widening cognitive and physical divides.

A study by MIT and Johns Hopkins involving 2,310 participants found that human-AI teams had 73% higher productivity and created higher-quality marketing content. In manufacturing, exoskeleton-supported workers experienced up to 60% less physical strain, while industry-wide implementations saw 20–60% injury reductions and 15–25% productivity gains. In healthcare, AI-assisted diagnostics increased fracture detection sensitivity from 72% to 80%, and specificity from 81% to 85%, while cutting diagnostic time by 30.8%. In law, AI-powered contract review achieved 98% accuracy and cut review time from 92 minutes to 26 seconds. Investment in longevity research reached $8.5 billion in 2024, a 220% increase over the previous year, reflecting growing interest in technologies that may extend productive working lives. The article highlights urgent ethical and policy questions, including neural data privacy, cognitive autonomy, and the risk of an enhancement divide between those with access to augmentation and those without.

Kudos to Beatriz Sanz Saiz for highlighting not just the tech, but the ethical, strategic, and societal shifts leaders need to navigate! It is a thought-provoking, even entertaining, and insightful weekend read, folks. Image credit: Ernst & Young Very happy to share the news of our new drug discovery collaboration with Eli Lilly! I must say that in my book, I rate Eli Lilly as #1 in terms of their approach to deploying end-to-end AI among all pharma companies with very strong internal generative AI and automation... They also deployed and integrated our generative AI tools in the most sophisticated way possible as lego blocks in the agentic AI platform.

So it is a great honor for us to be chosen as one of the drug discovery partners where we collaborate to discover novel therapeutics. I am also very happy that the partnership announcement coincides with Eli Lilly hitting all-time high 💡 Check out the BiopharmaTrend article and official press release in the comments. #pharma #longevity Pharmas have a record $1 trillion to deploy on new biotech innovation deals. All they need is for the Federal Reserve to lower rates, according to a new report from Ernst & Young. And that’s a big maybe.

The market is mostly betting that there will be one decrease in the second half, but the rates are expected to remain the same in the near term, according to the CME FedWatch Tool. But, if the pressure is relieved, biotech is poised for a comeback, according to EY’s latest Beyond Borders report published Monday. “Despite the Federal Reserve delaying action on interest rates, biotechs still have grounds for continued cautious optimism," said Arda Ural, Ph.D., EY Americas life sciences sector leader, in a statement. "The combination of record-level dealmaking capacity seen throughout 2023, firepower of Big Pharma and the healthy innovation capacity of the sector, including possibilities from artificial intelligence, will ultimately help the biotech sector to not... Event Date: April 29, 2026 - April 29, 2026 Location: Belgium (Brussels, Holiday Inn)

NEW YORK, June 18, 2025 /PRNewswire/ -- The 35th edition of the Ernst & Young LLP (EY US) Biotech Beyond Borders Report finds that the biopharma industry is currently in a challenging market. The industry is grappling with a unique environment of macroeconomic uncertainty and constrained access to capital such as high interest rates, inflation, shifting regulatory policies and tariff turmoil. This is the time for companies to focus on fundamentals and get ready to bounce back when the conditions improve. Arda Ural, PhD, EY Americas Life Sciences Sector Leader, says: "While predictions don't age well in this environment, there is light at the end of the tunnel. The biopharma industry has dealt with periods of uncertainty before, and 2025 will be a year of inflection during which companies will need to focus on the fundamentals, with scenario planning and cash efficiency...

Biotech Beyond Borders analyzes the state of the industry through a summary of US and European public company revenues, financing, M&A activity, alliances, product approvals and other factors. The report offers executives a deep dive into current dynamics as well as a perspective on the outlook. "During a challenging time for biopharma and biotech, the industry needs to look for the best ways to be efficient and extend cash runways," says Rich Ramko, EY Americas Life Sciences Sector and Biotechnology... "Successful companies and management teams will be those who embrace AI and new technologies to maximize efficiency and nurture innovation." BiopharmaTrend is a media and business intelligence resource that delves into the cutting-edge of drug discovery and development, healthcare and longevity, and biotech. Our expertise lies in uncovering the potential of artificial intelligence (AI), digital tools, advanced biology techniques, and data generation strategies, and tracking the most disruptive startups, scaleups, and more established companies in this field.

From CRISPR and gene editing to nanotechnology and mRNA therapies, we explore advancements that promise to redefine medical treatments and patient care. Our coverage extends to emerging fields such as bioprinting, synthetic biology, and quantum computing, highlighting their potential to revolutionize the biopharmaceutical industry. Our goal is to provide researchers, industry professionals, and investors with clear insights into market trends and opportunities for partnership and growth. The biotech industry stands at a crossroads, poised for a transformative era characterized by rapid innovation and significant financial challenges. The latest EY "Beyond Borders 2024" report provides a comprehensive overview of the trends, challenges, and opportunities that will shape the future of the biotech sector. Here’s a deep dive into the key insights that every biotech leader should know:

Despite recent financial challenges, biotech innovation is robust, driven by advancements in new therapeutic modalities and emerging technologies like AI and machine learning. The report highlights a notable shift towards revitalizing areas such as chronic diseases, which had previously fallen out of favor. This resurgence is fueling the development of new treatments for conditions affecting large patient populations, such as diabetes, obesity, and mental health disorders. Key Insight: Innovation in biotech is not slowing down. Companies are increasingly focusing on leveraging cutting-edge technologies to bring novel therapies to market, ensuring long-term growth and impact. The report paints a complex picture of the biotech financing landscape.

People Also Search

• Excited to see BioPharmaTrend.com cited in Ernst & Young (EY)'s latest ...
• EY 2025 Biotech Beyond Borders Report | EY - US
• Citations and Press Coverage - BiopharmaTrend
• BioPharmaTrend.com - LinkedIn
• Life sciences | EY - Global
• Pharma has $1T in firepower to spend on biotech innovation: EY
• BiopharmaTrend: Where Tech Meets Bio
• EY 2025 Biotech Beyond Borders Report: Biopharma -- Focus on ...
• About BioPharmaTrend
• Navigating the Future of Biotech: Key Insights from EY's ... - LinkedIn